Welcome to our dedicated page for DIAGNAMED HLDGS news (Ticker: DGNMF), a resource for investors and traders seeking the latest updates and insights on DIAGNAMED HLDGS stock.
DiagnaMed Holdings Corp. (OTCQB: DGNMF) is an artificial intelligence digital healthcare company focused on commercializing CERVAI™, a world-first consumer brain health and wellness AI solution. CERVAI™ estimates BRAIN AGE® and provides a brain health score, helping individuals detect potential brain health issues, assess cognitive decline, and seek personalized interventions. The company's CERVAI™ Brain Health commercial pilot program is available to clinics in Canada and the U.S., focusing on various healthcare sectors. For more information about CERVAI™ and joining the pilot program, visit the DiagnaMed website.
Rhea-AI Summary
DiagnaMed, a healthcare technology company, launches BRAIN AGE® Brain Health AI in Canada, offering a brain health and wellness AI solution for clinics. The Government of Ontario's investment in brain health initiatives could synergize with BRAIN AGE® to enhance brain health outcomes in the country.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
DiagnaMed Holdings Corp. expands its CERVAI™ Brain Health AI Platform by adding Drexel University as a test launch site. The platform estimates BRAIN AGE® and provides a brain health score, aiming to detect potential brain health issues and cognitive decline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
DiagnaMed Holdings Corp. receives approval for trademark registration of its BRAIN AGE® brand for commercial use in Canada, as part of its CERVAI™ Brain Health AI Platform. The company is expanding its commercial initiatives and collaborating with leading research hospitals in Canada. The CERVAI™ Brain Health commercial pilot program is available to clinics in Canada and the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
DiagnaMed Holdings Corp. announces potential $150,000 in non-dilutive funding support through IPON and IP Assist Programs to strengthen its intellectual property portfolio for commercializing CERVAI™ Brain Health AI solution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
DiagnaMed Holdings Corp. has been accepted into the HEALTHI program to accelerate clinical research and commercialization efforts in Canada for its CERVAI™ Brain Health AI Platform. The program aims to establish relationships with leading clinicians and hospital facilities to improve brain health assessment and intervention. CERVAI™ combines Brain Age™ Estimation and Brain Health Assessment tools to identify potential brain health issues, offering personalized diagnostics and interventions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
76.52%
Tags
-
Rhea-AI Summary
DiagnaMed Holdings Corp. announces the test launch of CERVAI™, a consumer brain health and wellness AI solution, at the University of Miami Comprehensive Center for Brain Health. The platform assesses brain health through a Resilience Index, Vulnerability Index, and Number-Symbol Coding Task, showing promising results in detecting Alzheimer's disease risk.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
DiagnaMed Holdings Corp. announced the pilot launch of CERVAI™, a consumer brain health and wellness AI solution that estimates brain age and provides a brain health score. The solution aims to help bridge gaps in physical and cognitive health, providing personalized interventions to improve overall brain health. CERVAI™ is based on research and development at Drexel University and the University of Miami, combining Brain Age™ Estimation and Brain Health Assessment tools. The pilot program is open to 25 consumer wellness clinics in the U.S. and Canada over the next three months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) has been accepted into the SOPHIE Program to accelerate clinical and commercialization efforts in Canada for the CERVAI™ Brain Health AI Platform. The program supports collaborative projects for Ontario-based life science firms in the later stages of commercialization. CERVAI™ consists of a Brain Age™ Estimation and Brain Health Assessment tool, integrating proprietary software and machine-learning models. The launch of the initial commercial version is expected in December 2023, with first sales to occur throughout Q1-2024. Discussions for international commercialization are underway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
DiagnaMed launches CERVAI™ Healthcare Provider Network to expand access to its brain health AI platform for healthcare providers. The program is open for enrollment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
DiagnaMed provides update on CERVAI™ commercialization
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of DIAGNAMED HLDGS (DGNMF)?
The current stock price of DIAGNAMED HLDGS (DGNMF) is $0.0127 as of November 21, 2024.
What is the market cap of DIAGNAMED HLDGS (DGNMF)?
The market cap of DIAGNAMED HLDGS (DGNMF) is approximately 1.7M.
What is DiagnaMed Holdings Corp. focused on?
DiagnaMed Holdings Corp. is focused on commercializing CERVAI™, a consumer brain health and wellness AI solution that estimates BRAIN AGE® and provides a brain health score.
What is CERVAI™?
CERVAI™ is a world-first AI solution developed by DiagnaMed Holdings Corp. It estimates BRAIN AGE® and provides a brain health score, helping individuals assess brain health issues and potential cognitive decline.
Where is the CERVAI™ Brain Health commercial pilot program available?
The CERVAI™ Brain Health commercial pilot program is available to clinics in Canada and the U.S., focusing on health and wellness, sports therapy, mental health, and more.
How can clinics join the CERVAI™ pilot program?
Clinics interested in joining the CERVAI™ pilot program can visit the DiagnaMed website for more information and details on participation.
What interventions can individuals seek through CERVAI™?
Individuals using CERVAI™ can seek personalized diagnostics and interventions, such as medication or lifestyle changes, to help decrease the development or progression of cognitive decline.
DIAGNAMED HLDGS CORP